Stock Under $10 with 50-100% upside potential - 14 Days FREE!

IPad Altering Interaction Between Pharma Sales Forces, Physicians, & Consumers

CHAPEL HILL, N.C., Feb. 1, 2013 /PRNewswire/ -- The integration of the iPad into the pharmaceutical industry has had a substantial impact on the sector's interactions with physicians and payers. The growth of tablet technology is rapidly transforming how field sales forces in the pharmaceutical industry communicate with physicians and payers.

While the implementation of the iPad has been rapid and exponential, effectively integrating iPads into the field requires significant planning and training to make the investment a success. A new benchmark study completed by research and consulting firm Best Practices, LLC uncovered strategies for measuring the effectiveness of the iPad as an inventive sales tool.

The report, Deploying the iPad to Sales & Managed Markets Teams: Training and Effectiveness Benchmark, focuses on key challenges and best practices when deploying iPads or Android-Based tablets to large customer-facing commercial groups within pharmaceutical and medical device organizations.

Among the findings that Best Practices uncovered:

  • Approximately one in five companies have already issued iPads to their managed markets teams, with an overall majority of benchmark companies planning to do so in the next 12 months.

The 66-page report contains over 130 metrics and 41 narratives to provide biopharmaceutical leaders with an evidence-based understanding of how other companies in the pharmaceutical and medical device industries are attempting to align their resources and activities to ensure the continuity of their sales' processes.

Key Topics of this report include:

  • Training
  • Systems Integration and Application Development
  • Security and Compliance
  • Applications that Increase Productivity
  • Field Usage and Measuring Effectiveness
  • Challenges and Best Practices in Making the Investment a Success

To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www3.best-in-class.com/rr1168.htm.

For more information on this study or other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

SOURCE Best Practices, LLC

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,303.10 8.60 0.06%
NASDAQ 3,459.14 -0.28 -0.01%
S&P 500 1,649.60 -0.91 -0.06%
US 10 Yr 2.011% -0.012

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs